Brain Targeting of Citicoline Sodium via Hyaluronic Acid-Decorated Novel Nano-Transbilosomes for Mitigation of Alzheimer’s Disease in a Rat Model: Formulation, Optimization, in vitro and in vivo Assessment

Abstract

Kariman M AbouElhassan,1,2 Hatem A Sarhan,1 Amal K Hussein,1 Ashraf Taye,3 Yasmin M Ahmed,4 Mohamed A Safwat5 1Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt; 2Faculty of Pharmacy, South Valley University, Qena, 83523, Egypt; 3Department of Pharmacology and Toxicology, Faculty of Pharmacy, South Valley University, Qena, 83523, Egypt; 4Department of Pharmacology and Toxicology, Faculty of Pharmacy, Nahda University, Beni-Suef, 62514, Egypt; 5Department of Pharmaceutics, Faculty of Pharmacy, South Valley University, Qena, 83523, EgyptCorrespondence: Kariman M AbouElhassan, Faculty of Pharmacy, South Valley University, El-Moatakal Street, Qena, Egypt, Tel [phone], Fax [phone], Email [email protected]: Alzheimer’s disease (AD) is one of the furthermost advanced neurodegenerative disorders resulting in cognitive and behavioral impairment. Citicoline sodium (CIT) boosts the brain’s secretion of acetylcholine, which aids in membrane regeneration and repair. However, it suffers from poor blood–brain barrier (BBB) permeation, which results in lower levels of CIT in the brain.Purpose: This study targeted to encapsulate CIT into novel nano-platform transbilosomes decorated with hyaluronic acid CIT-HA*TBLs to achieve enhanced drug delivery from the nose to the brain.Methods: A method of thin-film hydration was utilized to prepare different formulae of CIT-TBLs using the Box–Behnken design. The optimized formula was then hyuloranated via integration of HA to form the CIT-HA*TBLs formula. Furthermore, AD induction was performed by aluminum chloride (Alcl3), animals were allocated, and brain hippocampus tissue was isolated for ELISA and qRT-PCR analysis of malondialdehyde (MDA), nuclear factor kappa B (NF-kB), and microRNA-137 (miR-137) coupled with immunohistochemical amyloid-beta (Aβ1– 42) expression and histopathological finding.Results: The hyuloranated CIT-HA*TBLs formula, which contained the following ingredients: PL (300 mg), Sp 60 (43.97 mg), and SDC (20 mg). They produced spherical droplets at the nanoscale (178.94 ± 12.4 nm), had a high entrapment efficiency with 74.92± 5.54%, had a sustained release profile of CIT with 81.27 ± 3.8% release, and had ex vivo permeation of CIT with 512.43± 19.58 μg/cm2. In vivo tests showed that CIT-HA*TBL thermogel dramatically reduces the hippocampus expression of miR-137 and (Aβ1– 42) expression, boosting cholinergic neurotransmission and decreasing MDA and NF-kB production. Furthermore, CIT-HA*TBLs thermogel mitigate histopathological damage in compared to the other groups.Conclusion: Succinctly, the innovative loading of CIT-HA*TBLs thermogel is a prospectively invaluable intranasal drug delivery system that can raise the efficacy of CIT in Alzheimer’s management.Keywords: Alzheimer’s disease, transbilosomes, Box–Behnken design, intranasal drug delivery, brain targeting, in vivo study

Keywords

• alzheimer’s disease
• transbilosomes
• box– behnken design
• intranasal drug delivery
• brain targeting
• and in vivo study.